Oncobiologics

Oncobiologics signs two agreements worth $80 million

Thursday, October 13, 2011

Oncobiologics has signed two major agreements. The first is with Parilis Biopharmaceuticals, an early-stage biotech company, and involves worldwide licensing for an undisclosed biotherapeutic product. The second is with a US based pharmaceutical company to conduct research focused on solving issues related to downstream processing of monoclonal antibodies. The identity of the client firm was not disclosed due to confidentiality terms in the agreement. The combined value of the agreements to Oncobiologics totals close to $80 million.

[Read More]

Oncobiologics, Fox Chase Cancer Center to create cancer therapy platform

Monday, August 22, 2011

Oncobiologics and Fox Chase Cancer Center have agreed to co-develop a novel, next-generation bi-specific antibody cancer platform with enhanced therapeutic capabilities against solid tumors. The jointly engineered platform is designed to handle multiple targets, representing a pipeline of promising cancer treatments. This research program is now underway, with preclinical studies expected in Q1-2012 for the first molecule using this platform.

[Read More]